BACKGROUND AND AIMS: Infliximab (IFX) has been shown efficacious for moderate-to-severe ulcerative colitis (UC), but data on long-term efficacy are lacking. We investigated long-term outcome including colectomy rates in outpatients treated with IFX for refractory UC in a single referral centre, and evaluated if predictors could be identified. METHODS: The first 121 outpatients (median age 38.0 years) with refractory UC treated with IFX were included. The primary outcome was colectomy-free survival. Secondary measures were sustained clinical response and serious adverse events. RESULTS: From the 81 patients (67%) with an initial clinical response to IFX, 68% had a sustained clinical response. No independent predictors of sustained clinical response could be identified. Over a median (IQR) follow-up period of 33.0 (17.0-49.8) months, 21 patients (17%) came to colectomy. Independent predictors of colectomy were absence of short-term clinical response [Hazard ratio 10.8 (95% CI 3.5-32.8), p<0.001], a baseline CRP level ≥5 mg/L [Hazard ratio 14.5 (95% CI 2.0-108.6), p=0.006] and previous IV treatment with corticosteroids and/or cyclosporine [Hazard ratio 2.4 (95% CI 1.1-5.9), p=0.033]. Six patients developed a serious infection, three a malignancy, two a post-operative complication and one patient died (suicide). CONCLUSIONS: With a median follow-up of 33.0 months after start of IFX, 17% of patients with refractory UC needed colectomy, while sustained clinical response was present in 68% of initial responders.
BACKGROUND AND AIMS: Infliximab (IFX) has been shown efficacious for moderate-to-severe ulcerative colitis (UC), but data on long-term efficacy are lacking. We investigated long-term outcome including colectomy rates in outpatients treated with IFX for refractory UC in a single referral centre, and evaluated if predictors could be identified. METHODS: The first 121 outpatients (median age 38.0 years) with refractory UC treated with IFX were included. The primary outcome was colectomy-free survival. Secondary measures were sustained clinical response and serious adverse events. RESULTS: From the 81 patients (67%) with an initial clinical response to IFX, 68% had a sustained clinical response. No independent predictors of sustained clinical response could be identified. Over a median (IQR) follow-up period of 33.0 (17.0-49.8) months, 21 patients (17%) came to colectomy. Independent predictors of colectomy were absence of short-term clinical response [Hazard ratio 10.8 (95% CI 3.5-32.8), p<0.001], a baseline CRP level ≥5 mg/L [Hazard ratio 14.5 (95% CI 2.0-108.6), p=0.006] and previous IV treatment with corticosteroids and/or cyclosporine [Hazard ratio 2.4 (95% CI 1.1-5.9), p=0.033]. Six patients developed a serious infection, three a malignancy, two a post-operative complication and one patient died (suicide). CONCLUSIONS: With a median follow-up of 33.0 months after start of IFX, 17% of patients with refractory UC needed colectomy, while sustained clinical response was present in 68% of initial responders.
Authors: Carlos Taxonera; Manuel Barreiro-de Acosta; Marta Calvo; Cristina Saro; Guillermo Bastida; María D Martín-Arranz; Javier P Gisbert; Valle García-Sánchez; Ignacio Marín-Jiménez; Fernando Bermejo; María Chaparro; Ángel Ponferrada; María P Martínez-Montiel; Ramón Pajares; Celia de Gracia; David Olivares; Cristina Alba; Juan L Mendoza; Ignacio Fernández-Blanco Journal: Dig Dis Sci Date: 2015-06-05 Impact factor: 3.199
Authors: Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne Journal: Gut Date: 2019-09-27 Impact factor: 23.059
Authors: Edward Shelton; Jessica R Allegretti; Betsy Stevens; Matthew Lucci; Hamed Khalili; Deanna D Nguyen; Jenny Sauk; Cosmas Giallourakis; John Garber; Matthew J Hamilton; Michal Tomczak; Fredrick Makrauer; Robert B Burakoff; Jonathan Levine; Punyaganie de Silva; Sonia Friedman; Ashwin Ananthakrishnan; Joshua R Korzenik; Vijay Yajnik Journal: Inflamm Bowel Dis Date: 2015-12 Impact factor: 5.325
Authors: Laura Rosenberg; Garrett O Lawlor; Talia Zenlea; Jeffrey D Goldsmith; Anne Gifford; Kenneth R Falchuk; Jacqueline L Wolf; Adam S Cheifetz; Simon C Robson; Alan C Moss Journal: Inflamm Bowel Dis Date: 2013 Mar-Apr Impact factor: 5.325
Authors: Iris Detrez; Erwin Dreesen; Thomas Van Stappen; Annick de Vries; Els Brouwers; Gert Van Assche; Séverine Vermeire; Marc Ferrante; Ann Gils Journal: J Crohns Colitis Date: 2016-01-06 Impact factor: 9.071